Modelling the effectiveness of isolation strategies for managing mpox outbreaks with variable infectiousness profiles

AUTHORS:

Yong Dam Jeong¹, Takara Nishiyama¹, Hyeongki Park¹, Masahiro Ishikane², Noriko Iwamoto², Kazuyuki Aihara³, Koichi Watashi⁴, Eline Op de Coul⁵, William S Hart^{1,6}, Robin N Thompson⁶, Norio Ohmagari², Jacco Wallinga^{5,7}, Shingo Iwami^{1,3,8,9,10,11,12,†,*} and Fuminari Miura^{5,13,†,*}

AFFILIATIONS:

¹interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.²Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan. ³International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. ⁴Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan. ⁵Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. ⁶Mathematical Institute, University of Oxford, Oxford, OX2 6GG, UK. ⁷Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, the Netherlands. ⁸Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. ⁹Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. ¹⁰Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan.¹¹NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. ¹²Science Groove Inc., Fukuoka, Japan. ¹³Center for Marine Environmental Studies (CMES), Ehime University, Ehime, Japan.

^{*}To whom correspondence may be addressed.

Email: <u>iwami.iblab@bio.nagoya-u.ac.jp</u> (S.I.) and <u>fuminari.miura@rivm.nl</u> (F.M.)

1 Abstract

2 The global outbreak of mpox (formerly monkeypox) in 2022 raised public awareness 3 about the disease. The ensuing sporadic outbreaks in 2023 highlighted the importance of 4 sustaining nonpharmaceutical interventions, such as case isolation and contact tracing. Using 5 viral load data, we developed a modelling framework to characterize the various infectiousness 6 profiles of infected individuals. We used this model to examine the potential effectiveness of two 7 different possible isolation rules: specifically, rules permitting infected individuals to stop isolating 8 after either a fixed-duration or following negative tests for infection. Our analysis showed large individual variations in the duration of viral shedding, ranging from about 23 to 50 days. The risk 9 10 of infected individuals ending isolation too early (i.e., while they remained an infection risk) was 11 estimated to be about 5% after 3 weeks of isolation. Unnecessary isolation after the end of the 12 infectious period could be reduced by use of a testing-based rule. These findings support the 13 choice of a 3-week isolation period following symptom onset if a fixed-duration rule is used, but 14 also demonstrate how testing can mitigate unnecessarily prolonged isolation for those who have 15 shorter infectious periods.

16 Main Text

17 Since May 2022, a global outbreak of mpox (formerly monkeypox) has spread primarily 18 among men who have sex with men (MSM), first in European and North American countries, and later in other regions¹. Although growth of the outbreak was initially rapid, the global trend in 19 reported cases changed around the summer of 2022 and has been declining ever since². Recent 20 21 studies have suggested that the case saturation in many countries may be explained largely by infection-derived immunity accumulated among individuals who have many sexual partners³, 22 and the following decline in cases may have been accelerated by vaccination campaigns or 23 behavioral changes^{4,5}. However, since the beginning of 2023, sporadic outbreaks have been 24 25 reported, mainly in Asian countries, which were least affected by the 2022 outbreak and where vaccination campaigns had not yet been initiated, leading to a substantial number of individuals 26 27 remaining at risk of infection⁶. There are also reports of some breakthrough infections and reinfections in European countries^{7,8}. These findings warrant caution against a resurgence of 28 29 mpox and highlight the importance of maintaining nonpharmaceutical interventions (NPIs).

30 One essential NPI is case isolation. The effectiveness of isolation has been extensively studied in the context of COVID-19^{9,10} and other diseases^{11,12}. In general, if cases are detected 31 earlier (e.g., via contact tracing) and isolation begins sooner, a larger proportion of onward 32 transmissions can be prevented¹³. When determining the end of isolation, later is always safer, 33 as a longer isolation period minimizes the risk of releasing individuals who remain infectious. 34 35 However, case identification may require a substantial public health investigation effort, and redundant isolation induces societal cost and burden for individuals^{14,15}. Furthermore, more 36 stringent control strategies may also lead to reduced efficacy due to non-adherence¹⁶. To 37 mitigate these burdens, testing-based rules were applied during the COVID-19 pandemic^{17,18}, 38 39 which typically involved ending isolation following a specified number of successive negative PCR or antigen test results. Individual-level viral load data have been used to balance the 40 effectiveness and cost of isolation rules¹⁹, which is key to sustainable implementation. 41

42 Current guidelines for mpox generally suggest individuals who are exposed to the virus guarantine for about three weeks^{18,20-23} and refrain from sexual contact for 12 weeks after the 43 end of isolation²⁰. The three-week monitoring period is based on the estimated incubation 44 period^{24,25}, in which more than 98% of cases show symptoms within 21 days of exposure. 45 Although the exact duration of the infectious period is unclear, several studies have investigated 46 47 serial intervals (i.e., the time interval between symptom onset dates of primary and secondary 48 cases) and have suggested that, for symptomatic cases, more than 90% of transmission occurs within two weeks of symptom onset^{26,27}. Recent findings have also indicated that there might be 49 considerable heterogeneity in the infectious period between infected individuals. For example, 50 there is substantial variation in observed serial intervals²⁶, and some confirmed cases in Europe 51 exhibited prolonged viral shedding in their bodily fluids^{28,29}. Consequently, isolation rules that do 52 53 not account for heterogeneity between infected individuals (e.g. rules based on isolating for a fixed period following symptom onset) may lead to either a risk of ending isolation too early for 54 55 those who are still infectious, or an unnecessarily long isolation period for those who are no longer infectious. 56

57 In this study, we first characterize individual infectiousness profiles among mpox cases by analyzing longitudinal viral load data. We describe the time course of virus shedding using a 58 mathematical model that captures individual heterogeneity in the duration of viral clearance. We 59 60 then stratify the population according to the characterized shedding profiles and evaluate the 61 effectiveness of two different isolation rule types: a fixed-duration rule and a testing-based rule 62 (i.e., a tailored rule for individuals who test negative several times). Our study provides an approach to quantify both the risk of ending isolation too early and the period for which infected 63 64 individuals are isolated but do not pose an infection risk. Our model can be used by policy makers to inform decision making, allowing isolation strategies to be determined that balance cost and 65 effectiveness appropriately. 66

67 **Results**

68 Analyzed data and model fitting

We conducted a literature review of individual-level mpox patient data and identified a total 69 of 90 mpox cases with lesion samples meeting the inclusion criteria (see Methods). All cases 70 were symptomatic, and most of them were reported in Europe. To standardize the collected data. 71 72 we converted the reported cycle threshold values to viral load (copies/ml) using the conversion formula proposed in a previous study³⁰ (Supplementary Table 1). We then fitted the viral 73 74 clearance model to the longitudinal viral load data from lesion samples (Extended Data Fig. 1a and Supplementary Fig. 1). Estimated parameters suggested a median viral load of 10^{7.7} 75 copies/ml (95% CI: 10^{7.3}-10^{8.2}) at symptom onset. Additionally, a prolonged duration of viral 76 shedding was estimated: the viral load dropped below the detection limit (10^{2.9} copies/ml) 30.9 77 days (95% CI: 23.4-50.6) after symptom onset (Extended Data Fig. 1bc). This finding is 78 79 consistent with previous studies suggesting the persistent presence of mpox viruses in clinical specimens^{28,31}. 80

81

82 Stratification for mpox cases

The 90 analyzed mpox cases were stratified into three groups based on their estimated 83 individual parameters using the K-means clustering algorithm: Group 1 (medium risk of 84 85 transmission), Group 2 (high risk of transmission), and Group 3 (low risk of transmission) (Fig. 86 1a and 1b): Group 3 was characterized by a lower viral load at symptom onset and faster 87 clearance, whereas Group 2 was characterized by a higher viral load at symptom onset and 88 slower clearance. In addition, to compare the viral dynamics between the three groups, we 89 conducted statistical tests: Individuals in Group 2 had significantly higher viral loads at symptom onset than individuals in the other groups ($p < 1.0 \times 10^{-3}$ from the Mann-Whitney test). Also, 90 individuals in this group had a larger area under the viral load curve (AUC) ($p < 1.0 \times 10^{-3}$ from 91 the Mann-Whitney test), that is, the total amount of virus excreted between symptom onset and 92

93 the end of shedding. Viral clearance was significantly faster in Group 3 than in the other groups $(p < 1.0 \times 10^{-4}$ from the Mann-Whitney test) (Fig. 1c). To describe the difference in timing of 94 95 viral clearance, we additionally simulated the probability of detectable virus over time by using the model with estimated parameters for each group (Fig. 1d). In all stratified groups, the 96 97 probability was greater than 90% at 3 weeks after symptom onset. However, in the total group (i.e., a group of all analyzed cases), the probability dropped to 69.9% (95% CI: 67.0-73.2) at 4 98 99 weeks after symptom onset, which is the upper bound of the isolation period recommended by the CDC²¹. The probability in Group 3 at 4 weeks after symptom onset was 55.3% (95% CI: 100 51.8-55.0), whereas the corresponding probability in Group 2 was 90.6% (95% CI: 88.7-92.1). 101



103 Fig. 1: Stratification of mpox virus infections. a, Results of K-means clustering of mpox cases 104 based on estimated individual parameters. Data points indicate individuals and are colored 105 based on the group that each individual is in. The dimensions represent standardized estimated model parameters. b, Reconstructed individual mpox viral load trajectories in each group are 106 shown. Group 1, Group 2, and Group 3 represent cases with medium, high, and low risk of 107 108 transmission, respectively. c, Comparison between groups of: virus at symptom onset (left 109 panel); area under the viral load curve (AUC), i.e., the total amount of virus shed over time (middle panel); and duration of viral clearance (right panel), respectively. The Mann-Whitney test 110 111 was used to test for significant differences between groups. d, Viral clearance in each group. 112 Probability of detectable virus after symptom onset for each group (left panel). The solid lines and shaded regions indicate means and 95% confidence intervals, respectively. Bar plots 113 represent the probabilities for 3 weeks (right upper panel) and 4 weeks (right lower panel) after 114 115 symptom onset, respectively.

116 **Fixed-duration rule**

117 Under the estimated viral dynamics, we compared two types of rule for ending the isolation of mpox cases (fixed-duration and testing-based). To assess the effectiveness of the two rules, 118 119 we considered three metrics: 1) the risk of prematurely ending isolation, 2) the average infectious period after ending isolation (where this period was defined to be zero for individuals who isolate 120 121 beyond the duration of their infectious period), and 3) the average duration for which individuals 122 were isolated unnecessarily after the end of their infectious period (which could be positive or 123 negative). Whether an individual was infectious or not was ascertained based on a viral load threshold for infectiousness that was obtained from data on viral replication in cell culture^{28,32,33}. 124

125 Under a fixed-duration rule of ending isolation 3 weeks after symptom onset, the risk of ending isolation prematurely in the total group was estimated to be 5.4% (95% CI: 4.1-6.7). The 126 127 average duration for which individuals were isolated unnecessarily after the end of their infectious 128 period was 8.3 days (95% CI: 8.0-8.6). Group 3 had a lower risk of ending isolation prematurely of 0.7% (95% CI: 0.3-1.3), and a longer unnecessary isolation period of 10.4 days (95% CI: 129 130 10.2-10.6). However, in Group 2, a higher risk of 16.1% (95% CI: 13.9-18.1) was estimated, with 131 a shorter unnecessary isolation period of 4.6 days (95% CI: 4.2-4.9). To guarantee a risk of 132 prematurely ending isolation below 5% and an infectious period after ending isolation shorter than 1 day, we found that the total group, Group 1, Group 2, and Group 3 needed to be isolated for 22, 133 134 23, 26, and 17 days, respectively. In this case, the duration for which individuals were isolated 135 unnecessarily after the end of their infectious period was estimated to be 9.4, 8.1, 9.6, and 6.3 136 days for the total group, Group 1, Group 2, and Group 3, respectively (Fig. 2a).

137

138 **Testing-based rule**

For a fixed-duration rule, isolation of mpox cases ends after a fixed time period following symptom onset, so the three metrics considered here can be calculated based on the isolation period alone (**Fig. 2a**). By contrast, a testing-based rule is dependent on both the time interval between tests and the exact criterion used for ending isolation (see **Methods**). Under a criterion in which isolation ends following two consecutive negative results with daily testing (a criterion widely used for COVID-19)¹⁷, the total group had a risk of prematurely ending isolation of 52.2% (95% CI: 49.7-54.6), and the infectious period after ending isolation was calculated to be 2.3 days (95% CI: 2.1-2.5). Similarly, high risks of prematurely ending isolation, accompanied with an infectious period after ending isolation longer than 1 day, were estimated in the stratified groups (first-row and second-row panels in **Fig 2b**).

149 By varying the criteria (i.e., the required number of consecutive negative results and the 150 time interval between tests), different testing-based isolation strategies can be tested in terms of 151 their effects on the three metrics. The risk of prematurely ending isolation and the infectious 152 period after ending isolation decreased with a longer interval between tests and with a larger 153 number of consecutive negative results (first-row and second-row panels in Fig 2b), whereas the 154 duration for which individuals were isolated unnecessarily after the end of their infectious period 155 increased (third-row panels in Fig 2b). Under the conditions that the risk of prematurely ending 156 isolation is lower than 5% and infectious period after ending isolation is shorter than 1 day, the 157 minimum value of the unnecessary isolation period in the total group was 7.4 days (95% CI: 158 7.1-7.7) with three consecutive negative results and an interval of 5 days between tests. 159 Correspondingly, an isolation period of 20.1 days (95% CI: 19.7-20.5) was required on average 160 (purple triangles in **Fig 2b**). On the other hand, under the same conditions, stricter strategies were 161 needed for Group 2: four consecutive negative results and an interval of 2 days between tests 162 were needed to minimize the duration for which individuals were isolated unnecessarily after the 163 end of their infectious to 8.0 days (95% CI: 7.7-8.2), with a mean isolation period of 20.6 days 164 (95% CI: 20.1-21.0) (red triangles in Fig 2b).

165



Fig 2: Fixed-duration and testing-based rules for different groups. a, Fixed-duration rules. 167 The risk of prematurely ending isolation for different isolation periods (left panel). The black 168 horizontal line corresponds to 5%. Infectious period after ending isolation for different isolation 169 170 periods (middle panel). The grey horizontal line corresponds to 1 day. The time period for which 171 individuals were isolated unnecessarily after the end of their infectious period for different 172 isolation periods (right panel). The circles correspond to the points with the lowest unnecessarily prolonged isolation period for which the following conditions are satisfied: i) the risk of 173 174 prematurely ending isolation was required to be lower than 5% and ii) the infectious period after 175 ending isolation was required to be shorter than 1 day. The shaded regions in each panel indicate 95% confidence intervals. b, Testing-based rules. The risk of prematurely ending 176

177 isolation (first row of panels), the infectious period after ending isolation (second row of panels), 178 the isolation period following the end of infectiousness (third row of panels), and the optimal 179 isolation period (fourth row of panels) are shown for different intervals between PCR tests and 180 numbers of consecutive negative results necessary to end isolation. The areas surrounded by 181 black and grey lines are those with 5% or lower risk of prematurely ending isolation and with 1 182 day or shorter infectious period after ending isolation, respectively. The triangles correspond to 183 the points with the shortest isolation period following the end of infectiousness for which both 184 conditions noted above are satisfied. Color keys and symbols apply to all panels. Note that the 185 estimated values are based on 100 independent simulations.

Comparison between fixed-duration and testing-based rules for ending isolation

187 To highlight the difference between fixed-duration and testing-based rules for each group, we compared the two types of rule by computing the optimal isolation strategies in which the 188 189 isolation period following the end of infectiousness is minimized while ensuring that the risk of 190 prematurely ending isolation is less than 5% and the infectious period after ending isolation is less 191 than 1 day. For testing-based rules, the mean isolation period that the optimal strategies then lead 192 to can be computed for each stratified group. In the total group, the optimized fixed-duration and 193 testing-based rules gave isolation periods of 22 and 20.1 days, resulting in minimized 194 unnecessary isolation periods of 9.4 and 7.4 days, respectively (Extended Data Fig. 2). In Group 195 2, the testing-based rule led to an unnecessary isolation period that was 1.4 days shorter than the 196 fixed-duration rule, whereas Groups 1 and 3 showed similar unnecessary isolation periods when 197 either rule was applied. However, compared with the fixed-duration rule in the total group, the 198 testing-based rule in Group 3 could reduce the optimal isolation period and the unnecessarily 199 isolation period to 17.1 days and 6.5 days, respectively.

200 As a sensitivity analysis, we varied the assumed infectiousness threshold and investigated 201 the corresponding difference in the period for which individuals were isolated unnecessarily after 202 the end of their infectious period between the two rules (Supplementary Fig. 2). When the 203 infectiousness threshold is higher, the corresponding infectious period becomes shorter, leading 204 to a shorter required isolation period and shorter period of unnecessary isolation given the same 205 acceptable risk. Our analysis showed that a higher infectiousness threshold resulted in smaller 206 differences between the two rules for each stratified group (Supplementary Fig. 2), which was 207 consistent with our previous findings for COVID-19⁹.

208

209 Comparison between lesion and other samples for infectiousness after ending isolation

To demonstrate that lesion samples are suitable for designing isolation rules, we compared the viral dynamics that we inferred using lesion samples to analogous results obtained using other samples. Specifically, we used longitudinal viral load data measured in upper

213 respiratory tract, blood, and semen samples from the same mpox cases to estimate mpox virus 214 dynamics in those samples (Supplementary Table 1 and Extended Data Fig. 3a). Following 215 symptom onset, other samples exhibited lower viral loads compared with lesion samples. In 216 particular, at the optimal ending isolation period of 22 days under a fixed-duration rule, the viral 217 load in lesion samples was substantially higher than in other samples (Extended Data Fig. 3b). 218 Moreover, we compared the predicted infectiousness when lesion samples and other samples 219 are used by computing the proportion of individuals who remained infectious on day 22 after 220 symptom onset. Around 3% of individuals were estimated to be infectious when lesion samples 221 were used, whereas the viral load never exceeded the infectiousness threshold for the other 222 samples (Extended Data Fig. 3c). This suggests that infectious mpox cases may be missed if we implement a testing-based rule with samples other than lesion samples. 223

224 **Discussion**

225 In this study, we have compared different strategies that can be implemented to determine 226 when mpox infected individuals stop isolating. If a single population-wide fixed-duration isolation 227 strategy is used, then we found that allowing individuals to end their isolation after a period of 228 three weeks following symptom onset is a reasonable threshold. Under this strategy, more than 229 95% of onward transmissions would be prevented. Our modelling analysis showed that there was 230 individual heterogeneity in viral shedding kinetics, indicating that the use of testing-based rules 231 may reduce the period for which infected individuals with a shorter duration of virus shedding are 232 required to isolate.

233 We observed different shedding kinetics between patients in the analyzed data. We 234 therefore stratified the patients based on their viral load during the decay phase of infection (Fig. 235 1). Variations in virus shedding may lead to substantial heterogeneity in infectiousness between 236 individuals. For mpox, existing studies have focused on individual variations in the number of sexual contacts or partners^{4,34}, because higher contact rates generally result in a larger number of 237 238 secondary cases. In contrast, variations in viral shedding have received limited attention to date. 239 Our study found that some mpox cases exhibit a 5–10-day shorter (or longer) duration of virus 240 shedding than the average. Individuals in those groups may thus contribute to virus transmission 241 for shorter (or longer) periods, resulting in a lower (or higher) number of secondary cases. When 242 designing tailored interventions to ensure that the time-dependent reproduction number, R (the average number of secondary cases generated by each infected individual)³⁵, is below one (i.e., 243 244 the outbreak is declining), our approach provides a way to incorporate such heterogeneity in the 245 infectious period by using individual viral load as a proxy.

For evaluating the risk of transmission following the end of isolation, the use of longitudinal viral load data may be advantageous over symptom-based approaches. One difficulty lies in the inherent uncertainty in self-reported symptoms; many confirmed mpox cases have been found to be not fully aware of their symptoms at the time of reporting³⁶. Viral load data have the potential to provide more objective and quantitative criteria for ending isolation³⁷. If viral load data are used,

251 measuring viral load in lesion samples (rather than the other sample types that we considered) is 252 the safest choice, as lesion samples showed the highest viral load and the longest detectable 253 period (**Extended Data Fig. 3**).

254 Isolation rules need to balance the risk of releasing infectious cases prematurely and the societal burden of extended isolation. Our results indicate that optimized fixed-duration and 255 256 testing-based rules can result in comparable risk levels if the same rule is applied to all cases. By 257 contrast, the total duration of unnecessary isolation can be reduced using a testing-based rule. It 258 is possible to shorten the isolation period for those with faster viral clearance, leading to a reduced 259 burden at the population level. A testing-based approach may also be beneficial for evaluating the 260 times at which individuals can resume sexual activities. Despite the current recommendation of using a condom for 12 weeks after scabs have fallen off as a precaution²⁰, having additional 261 262 information about patients' infectiousness would offer reassurance to them and help to prevent 263 discrimination and stigma related to sexual behaviors. As outlined in Extended Data Fig. 3c, our 264 assessment revealed that viral load in semen had fallen below the infectiousness threshold by the 265 endpoint of an optimized 22-day isolation period.

266 As with any modelling analysis, there are several limitations to our study. First, our analysis relied on the patient data collected, which may not be representative of all mpox cases in the 267 268 affected population. The estimated parameters were obtained using data from untreated patients, 269 but in outbreak settings antiviral drugs such as tecovirimat may be provided to infected individuals 270 and used prophylactically. Further investigations into the association between clinical 271 characteristics of patients, treatments, and viral load would be needed for a more granular 272 understanding of heterogeneous infectiousness profiles. This may enable, for example, different 273 fixed-duration isolation periods to be specified for individuals with different characteristics. 274 Second, the association between mpox viral load and infectiousness needs to be understood 275 more deeply. Specifically, based on experimental data on viral culturability, we used 10⁶ copies/ml as the infectiousness threshold value in main analysis; however, this involves 276 uncertainty^{28,32,33}. Accordingly, we performed sensitivity analyses (**Supplementary Fig. 2**) and 277

found similar results regardless of the assumed threshold value. Last, our analysis did not capture external sources of uncertainty affecting the false-negative rate of testing. In practical settings, imperfect swab sampling, especially with self-collection, could occur (leading to differential test specificity/sensitivity). There may also be cases who repeatedly get tested until obtaining a negative result, as occurred during the COVID-19 pandemic³⁸. Such challenges need to be considered when implementing testing-based rules.

284 In conclusion, this study provides empirical evidence for heterogeneity in virus shedding 285 kinetics and infectiousness among mpox cases and describes the impact of such heterogeneity 286 on the effectiveness of different isolation rules. Rules that recommend isolating following a fixed 287 period after being exposed to the virus are straightforward to apply, and can be effective at preventing transmission. Rules that are instead based on obtaining negative test results prior to 288 289 ending isolation are more nuanced and can have advantages, for example by reducing the 290 period for which some individuals are required to isolate after they are no longer infectious. 291 Careful consideration of the benefits and drawbacks of different strategies for ending isolation is 292 essential. Ensuring sustainable implementation of NPIs remains key to responding effectively to 293 future outbreaks of mpox.

294 **METHODS**

295 Viral load data

We searched the literature for longitudinal data from mpox cases meeting the following criteria: 1) viral load was measured at least at two different time points; 2) viral load was measured in different samples including lesion samples; and 3) patients did not receive any antivirals (as our model does not consider antiviral treatment). A total of 7 publications met those criteria, and 90 mpox cases were identified. We used only de-identified data from published studies and thus ethics approval was not required.

302

303 Modelling mpox viral clearance and parameter estimation

Using the viral load data, we parameterized a mathematical model of temporal viral clearance dynamics in each infected individual. For this, we employed an exponential decay model, which was previously utilized in an mpox study²⁸:

$$\frac{dV(t)}{dt} = -\delta V(t),$$

where the variable V(t) is the viral RNA load (copies/ml) at time t and parameter δ represents the viral clearance rate. Note that the timescale is time after symptom onset; t = 0 is thus the date on which symptoms of mpox first began. V(0) is the initial viral load at symptom onset.

310 A nonlinear mixed-effect model was used to estimate the parameters δ and $V(0)^{9,10}$. This 311 approach captures the heterogeneity in the viral dynamics by including both a fixed effect (the 312 shared effect among individuals, i.e., population parameter) and a random effect (the 313 individual-level effect) in each parameter. Population parameters and the standard deviation of 314 random effects were estimated by using the Stochastic Approximation Expectation Maximization 315 algorithm to compute the maximum likelihood estimator of the parameters, assuming a Gaussian 316 distribution (mean 0 and variance σ^2) for the residuals (i.e., differences between predicted log viral load and measured log viral load) to quantify the error used in our simulations³⁹. Individual 317

318 parameters were subsequently computed using Markov Chain Monte Carlo (MCMC). The

319 estimation procedures were performed using MONOLIX 2023R1 (<u>www.lixoft.com</u>).

320

321 Clustering algorithm to stratify mpox cases

We stratified the mpox cases using the K-means clustering algorithm⁴⁰, which finds cluster assignments by minimizing the sum of squared Euclidean distances between estimated parameter sets. We first standardized the estimated parameters, since the two parameters in the viral clearance model have different units. Then, the algorithm partitioned the set of estimated individual parameters into *k* clusters. The optimal number of clusters was determined by the Silhouette method⁴¹.

328

329 Simulation of viral dynamics and different rules for ending isolation

330 To account for individual variability in viral dynamics when determining the optimal duration 331 of isolation, we simulated the predicted viral load, V(t), for 1000 virtual patients by running the 332 viral clearance model. Parameter sets for each virtual patient were sampled from distributions of estimated model parameters. The measured viral load, $\hat{V}(t)$, was obtained from the following 333 equation: $\log_{10} \hat{V}(t) = \log_{10} V(t) + \varepsilon, \varepsilon \sim N(0, \sigma^2)$, where ε is the error term. For each individual, 334 335 the residuals were calculated at all measurement time points, and by fitting the Gaussian distribution to all computed residuals, the variance of error, σ^2 , was estimated. For parameter 336 337 sets for virtual patients in each stratified group, we used individual parameters drawn from 338 conditional distributions (i.e., distributions conditioned on the observed data and the estimated 339 population parameters) characterizing the estimated parameters for individuals in each group, as 340 estimated in the MCMC procedure.

Under a fixed-duration rule, it was assumed that isolation would end at a specified time following symptom onset. On the other hand, under testing-based rules using PCR tests, isolation ended when a given number of consecutive negative results was met with a given interval between tests. Here, we assumed that patients began to take tests immediately following

345 symptom onset. To simulate various situations, we varied the interval between tests (from 1 to 5 346 days) and the number of consecutive negative results (from 1 to 5 times). To ascertain individuals' infectious periods, a viral load threshold of infectiousness was considered. If the viral load of a 347 348 patient was above the threshold, the patient was considered as being infectious. The threshold values considered were obtained from studies on viral replication in cell culture^{28,32,33}. In this study, 349 we set 10⁶ copies/ml as the main threshold value. However, this value is still uncertain and thus 350 we also considered different threshold values from 10⁵ copies/ml to 10⁷ copies/ml as sensitivity 351 352 analyses. For the evaluation of different rules, three metrics were computed: 1) risk of prematurely ending isolation, 2) infectious period after ending isolation, and 3) unnecessarily 353 354 prolonged isolation period. The first metric gives the probability of releasing patients while they are still infectious. The second metric is defined as the mean number of days for which patients 355 356 remain infectious after they are released from isolation (defined to be zero for an individual who is 357 no longer infectious when released from isolation). The third metric gives the mean difference 358 between the time when patients are no longer infectious and the time at which their isolation ends^{9,10} (which is negative for individuals who are infectious beyond the end of isolation). 359 360 Specifically, the prematurely ending isolation computed risk of was as $\sum_{i} I(V_i(\tau_i) > | \text{nfectiousness threshold})/1000$, where I is the indicator function, V_i is the 361 362 predicted viral load of patient i, and τ_i is the time when isolation of patient i ends. We computed the infectious period after ending isolation by use of the following formula: $\sum_i \max(0, \bar{\tau}_i - \tau_i)/$ 363 1000, where $\bar{\tau}_i$ indicates the time when the predicted viral load of patient i drops below the 364 infectiousness threshold. Finally, the unnecessarily prolonged isolation period was calculated as 365 $\sum_i (\tau_i - \bar{\tau}_i)/1000$. By running 100 simulations (1000 patients for each simulation), we reported the 366 367 mean and 95% confidence intervals for distributions of those three metrics, respectively. All analyses were conducted using the statistical computing software R (version 4.2.3). 368

369 LIST OF SUPPLEMENTARY MATERIALS

- **Supplementary Fig. 1**: Estimated individual viral load trajectory for each mpox case with lesion
- 371 samples
- 372 Supplementary Fig. 2: Comparison between fixed-duration and testing-based rules depending
- 373 on different infectiousness thresholds
- **Supplementary Fig. 3**: Estimated individual viral load trajectory for each mpox case with different
- 375 samples
- **Supplementary Table 1**: Summary of mpox viral load data with different samples
- 377 Supplementary Table 2: Estimated fixed effect parameters, standard deviation of random effect,
- 378 and standard deviation of error in mpox viral loads for each sample

380 **REFERENCES**

- 3811Vaughan, A. M. *et al.* A large multi-country outbreak of monkeypox across 41 countries in the
WHO European Region, 7 March to 23 August 2022. *Euro Surveill* 27,
L is 10 2007/1560 7017 EU 2022 27 26 2009/20 (2022)
- 383 doi:10.2807/1560-7917.ES.2022.27.36.2200620 (2022).
- 3842World Health Organization. 2022-23 Mpox Outbreak: Global Trends,385<<u>https://worldhealthorg.shinyapps.io/mpx_global/</u>> (2023).
- 3 Murayama, H. *et al.* Accumulation of immunity in heavy-tailed sexual contact networks shapes
 mpox outbreak sizes. *J Infect Dis*, doi:10.1093/infdis/jiad254 (2023).
- 3884Xiridou, M. *et al.* The fading of the mpox outbreak among men who have sex with men: a
mathematical modelling study. *medRxiv*, 2023.2001.2031.23285294,3891.1011010022.01.21.22285204 (2022)
- 390 doi:10.1101/2023.01.31.23285294 (2023).
- Brand, S. P. C. *et al.* The role of vaccination and public awareness in forecasts of Mpox incidence
 in the United Kingdom. *Nat Commun* 14, 4100, doi:10.1038/s41467-023-38816-8 (2023).
- Endo, A., Jung, S. M. & Miura, F. Mpox emergence in Japan: ongoing risk of establishment in
 Asia. *Lancet* 401, 1923-1924, doi:10.1016/S0140-6736(23)00766-3 (2023).
- Thy, M. *et al.* Breakthrough Infections after Postexposure Vaccination against Mpox. *N Engl J Med* 387, 2477-2479, doi:10.1056/NEJMc2211944 (2022).
- Raccagni, A. R. *et al.* Two individuals with potential monkeypox virus reinfection. *Lancet Infect Dis* 23, 522-524, doi:10.1016/S1473-3099(23)00185-8 (2023).
- Jeong, Y. D. *et al.* Revisiting the guidelines for ending isolation for COVID-19 patients. *Elife* 10, doi:10.7554/eLife.69340 (2021).
- 401 10 Jeong, Y. D. *et al.* Designing isolation guidelines for COVID-19 patients with rapid antigen tests.
 402 *Nat Commun* 13, 4910, doi:10.1038/s41467-022-32663-9 (2022).
- Muller, J. & Kretzschmar, M. Contact tracing Old models and new challenges. *Infect Dis Model*6, 222-231, doi:10.1016/j.idm.2020.12.005 (2021).
- Alpalhao, M. & Filipe, P. The Impacts of Isolation Measures Against SARS-CoV-2 Infection on
 Sexual Health. *AIDS Behav* 24, 2258-2259, doi:10.1007/s10461-020-02853-x (2020).
- 13 Kretzschmar, M. E. *et al.* Impact of delays on effectiveness of contact tracing strategies for
 13 COVID-19: a modelling study. *Lancet Public Health* 5, e452-e459,
 109 doi:10.1016/S2468-2667(20)30157-2 (2020).
- Ash, T., Bento, A. M., Kaffine, D., Rao, A. & Bento, A. I. Disease-economy trade-offs under
 alternative epidemic control strategies. *Nat Commun* 13, 3319, doi:10.1038/s41467-022-30642-8
 (2022).
- Hossain, M. M., Sultana, A. & Purohit, N. Mental health outcomes of quarantine and isolation for infection prevention: a systematic umbrella review of the global evidence. *Epidemiol Health* 42, e2020038, doi:10.4178/epih.e2020038 (2020).
- Leng, T., Hill, E. M., Keeling, M. J., Tildesley, M. J. & Thompson, R. N. The effect of
 notification window length on the epidemiological impact of COVID-19 contact tracing mobile
 applications. *Commun Med (Lond)* 2, 74, doi:10.1038/s43856-022-00143-2 (2022).
- 17 *Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in* 120 *healthcare settings (interim guidance)*, https://stacks.cdc.gov/view/cdc/88538 (2020).
- 12118Infection Prevention and Control of Mpox in Healthcare Settings,122https://www.cdc.gov/poxvirus/mpox/clinicians/infection-control-healthcare.html> (2022).
- Maya, S. & Kahn, J. G. COVID-19 testing protocols to guide duration of isolation: a
 cost-effectiveness analysis. *BMC Public Health* 23, 864, doi:10.1186/s12889-023-15762-0 (2023).
- 125 20 UK Health Security Agency. Mpox (monkeypox): people who are isolating at home,
 126 https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating
 127 https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating
 127 https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating
 127 https://www.gov.uk/guidance/guidance-for-people-with-monkeypox-infection-who-are-isolating

12821Centers for Disease Control and Prevention (CDC). Isolation and Prevention Practices for129People with Mpox, <<u>https://www.cdc.gov/poxvirus/mpox/clinicians/isolation-procedures.html</u>>130(2023).

431	22	European Centre for Disease Prevention and Control. Guidance on ending the isolation period
432		for people with COVID-19, third update,
433		<https: covid-19-guidance-discharge-and-ending-isolat<="" en="" publications-data="" td="" www.ecdc.europa.eu=""></https:>
134		<u>ion</u> >(2022).
435	23	National Institute for Public Health and the Environment. Information letter for a person with
436		<i>monkeypox</i> , < <u>https://lci.rivm.nl/information-letter-person-monkeypox</u> > (2022).
137	24	Miura, F. et al. Estimated incubation period for monkeypox cases confirmed in the Netherlands,
438		May 2022. Euro Surveill 27, doi:10.2807/1560-7917.ES.2022.27.24.2200448 (2022).
139	25	Guzzetta, G. et al. Early Estimates of Monkeypox Incubation Period, Generation Time, and
140		Reproduction Number, Italy, May-June 2022. Emerg Infect Dis 28, 2078-2081,
141		doi:10.3201/eid2810.221126 (2022).
142	26	Miura, F. et al. Time scales of human mpox transmission in the Netherlands. J Infect Dis,
143		doi:10.1093/infdis/jiad091 (2023).
144	27	Madewell, Z. J. et al. Serial Interval and Incubation Period Estimates of Monkeypox Virus
145		Infection in 12 Jurisdictions, United States, May-August 2022. Emerg Infect Dis 29, 818-821,
146		doi:10.3201/eid2904.221622 (2023).
147	28	Suner, C. <i>et al.</i> Viral dynamics in patients with monkeypox infection: a prospective cohort study
148		in Spain. Lancet Infect Dis 23, 445-453, doi:10.1016/S1473-3099(22)00794-0 (2023).
149	29	Gaspari, V. et al. Monkeypox Outbreak 2022: Clinical and Virological Features of 30 Patients at
450		the Sexually Transmitted Diseases Centre of Sant' Orsola Hospital, Bologna, Northeastern Italy, J
451		<i>Clin Microbiol</i> 61 , e0136522, doi:10.1128/jcm.01365-22 (2023).
452	30	Luciani, L. et al. A novel and sensitive real-time PCR system for universal detection of
453		poxviruses. Sci Rep 11, 1798, doi:10.1038/s41598-021-81376-4 (2021).
154	31	Kapmaz, M. et al. A complicated case of monkeypox and viral shedding characteristics. J Infect
455		86 , 66-117, doi:10.1016/j.jinf.2022.10.020 (2023).
156	32	Saijo, M. <i>et al.</i> Diagnosis and assessment of monkeypox virus (MPXV) infection by quantitative
157		PCR assay: differentiation of Congo Basin and West African MPXV strains. Jpn J Infect Dis 61.
158		140-142 (2008).
159	33	Norz, D. <i>et al.</i> Evidence of surface contamination in hospital rooms occupied by patients infected
160		with monkeypox, Germany, June 2022. Euro Surveill 27,
461		doi:10.2807/1560-7917.ES.2022.27.26.2200477 (2022).
462	34	Endo, A. <i>et al.</i> Heavy-tailed sexual contact networks and monkeypox epidemiology in the global
463		outbreak, 2022. Science 378 , 90-94, doi:10.1126/science.add4507 (2022).
164	35	Thompson, R. N. et al. Improved inference of time-varying reproduction numbers during
165		infectious disease outbreaks. <i>Epidemics</i> 29 , 100356, doi:10.1016/j.epidem.2019.100356 (2019).
166	36	De Baetselier, I. <i>et al.</i> Retrospective detection of asymptomatic monkeypox virus infections
467		among male sexual health clinic attendees in Belgium. Nat Med 28, 2288-2292,
168		doi:10.1038/s41591-022-02004-w (2022).
469	37	Ejima, K. et al. Estimation of the incubation period of COVID-19 using viral load data. Epidemics
170		35 , 100454, doi:10.1016/i.epidem.2021.100454 (2021).
171	38	Mouliou, D. S. & Gourgoulianis, K. I. False-positive and false-negative COVID-19 cases:
172		respiratory prevention and management strategies, vaccination, and further perspectives. <i>Expert</i>
173		<i>Rev Respir Med</i> 15 , 993-1002, doi:10.1080/17476348.2021.1917389 (2021).
174	39	Kuhn, E. & Lavielle, M. Maximum likelihood estimation in nonlinear mixed effects models.
175	•••	Computational statistics & data analysis 49, 1020-1038 (2005).
176	40	Sammut, C. & Webb, G. I. <i>Encyclopedia of machine learning</i> . (Springer Science & Business
177		Media. 2011).
178	41	Rousseeuw, P. J. & Kaufman, L. Finding groups in data: An introduction to cluster analysis
179		(John Wiley & Sons Hoboken, New Jersey, 2009).
180		······································
481		

482 ACKNOWLEDGMENTS

183 This study was supported in part by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2022R1C1C2003637) (to K.S.K.); Scientific 184 185 Research (KAKENHI) B 23H03497 (to S.I.): Grant-in-Aid for Transformative Research Areas 186 22H05215 (to S.I.): Grant-in-Aid for Challenging Research (Exploratory) 22K19829 (to S.I.): 187 AMED CREST 19gm1310002 (to S.I.); AMED Research Program on Emerging and Re-emerging 188 Infectious Diseases 22fk0108509 (to S.I.), 23fk0108684 (to S.I.), 23fk0108685 (to S.I.); AMED 189 Research Program on HIV/AIDS 22fk0410052 (to S.I.); AMED Program for Basic and Clinical 190 Research on Hepatitis 22fk0210094 (to S.I.); AMED Program on the Innovative Development and 191 the Application of New Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic 192 Research Program for Brain Sciences 22wm0425011s0302; AMED JP22dm0307009 (to K.A.); 193 JST MIRAI JPMJMI22G1 (to S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and 194 JPMJMS2025 (to S.I.); Institute of AI and Beyond at the University of Tokyo (to K.A.); Shin-Nihon 195 of Advanced Medical Research (to S.I.); SECOM Science and Technology Foundation (to S.I.); 196 The Japan Prize Foundation (to S.I.). The collaboration between R.N.T. and S.I. was supported 197 by a Royal Society International Exchange award (grant number IES-R3-193037).

198

AUTHOR CONTRIBUTIONS

500 SI and FM designed the research. YDJ carried out the computational analysis. SI and FM 501 supervised the project. All authors discussed the research and contributed to writing the 502 manuscript.

503

504 COMPETING FINANCIAL INTERESTS

505The authors declare no conflicts of interest associated with this manuscript.506



509 **Extended Data Fig. 1: Characterization of mpox virus infection dynamics. a**, Estimated viral 510 load trajectory for mpox cases with lesion samples. The solid line is the estimated viral load 511 trajectory under the best-fit fixed effect parameters. The shaded regions indicate 95% prediction 512 intervals computed using a bootstrap approach. **b**, Distributions of estimates of the viral RNA 513 load at symptom onset (upper panel) and distributions of estimates of the duration of viral 514 shedding (lower panel). The vertical dashed lines indicate median values.



517 Extended Data Fig. 2: Comparison between fixed-duration and testing-based rules for different groups. The circles and triangles represent fixed-duration and testing-based rules, 518 519 respectively. Each symbol represents the mean length of isolation using the strategy that 520 minimizes unnecessarily prolonged isolation under the conditions that the risk of prematurely 521 ending isolation is less than 5% and the infectious period after ending isolation is less than 1 day. 522 Note that for testing-based rules, the interval between tests and the number of consecutive 523 negative results necessary to end isolation were chosen to minimize the unnecessarily 524 prolonged isolation period.



527 Extended Data Fig. 3: Comparison of mpox virus infection between lesion samples and other samples. a, Estimated viral load trajectories for mpox cases with different samples. The 528 solid lines are estimated viral load trajectories for the best-fit parameters of fixed effect. The 529 shaded regions indicate 95% prediction intervals computed using a bootstrap approach. The 530 purple, yellow, orange, and grey colors correspond to lesion, upper respiratory, blood, and 531 532 semen samples, respectively. b, Distribution of viral RNA load with different samples at the end 533 of isolation. c, Proportion of infectious individuals with different samples (%) at the end of 534 isolation. Note that the optimal ending isolation period of 22 days under a fixed-duration rule was used as the end of isolation. Color keys apply to all panels. 535